SEC Company Response from ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510) (VISK) — Nov 30, 2009
ENZON PHARMACEUTICALS, INC. (ENZN) (CIK 0000727510)
Date: Nov. 30, 2009 · CIK: 0000727510 · Accession: 0001341004-09-002369
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-12957
Referenced dates: November 25, 2009
Letter
VIA EDGAR TRANSMISSION Division of Corporation Finance Securities and Exchange Commission Enzon Pharmaceuticals, Inc. Preliminary Proxy Statement Filed on November 23, 2009 File No. 000-12957
Dear Mr. Krug:
In response to your request in the letter dated November 25, 2009 relating to the above-referenced filing on Schedule 14A, Enzon Pharmaceuticals, Inc. (the "Company") hereby acknowledges the following:
1.
The Company is responsible for the adequacy and accuracy of the disclosure in the Company's filing;
2.
Comments from the Staff (the "Staff") of the Securities and Exchange Commission (the "Commission") or changes to disclosure in response to Staff comments do not foreclose the Commission from taking any action with respect to the filing; and
3.
The Company may not assert Staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Very
truly yours,
ENZON
PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
enzon.htm
Enzon
Pharmaceuticals, Inc.
685
Route 202/206
Bridgewater,
NJ 08807
November
30, 2009
VIA
EDGAR TRANSMISSION
John
L. Krug, Esq.
Senior
Counsel
Division
of Corporation Finance
Securities
and Exchange Commission
100
F Street, N.E.
Washington,
D.C. 20549-4720
Re:
Enzon
Pharmaceuticals, Inc.
Preliminary
Proxy Statement
Filed
on November 23, 2009
File No. 000-12957
Dear
Mr. Krug:
In
response to your request in the letter dated November 25, 2009 relating to the
above-referenced filing on Schedule 14A, Enzon Pharmaceuticals, Inc. (the
"Company") hereby acknowledges the following:
1.
The
Company is responsible for the adequacy and accuracy of the disclosure in
the Company's filing;
2.
Comments
from the Staff (the "Staff") of the Securities and Exchange Commission
(the "Commission") or changes to disclosure in response to Staff comments
do not foreclose the Commission from taking any action with respect to the
filing; and
3.
The
Company may not assert Staff comments as a defense in any proceeding
initiated by the Commission or any person under the federal securities
laws of the United States.
Very
truly yours,
ENZON
PHARMACEUTICALS, INC.
By:
/s/
Craig A. Tooman
Name:
Craig
A. Tooman
Title:
EVP
Finance and CFO
cc:
Susanne
Hayes, Esq., Securities and Exchange Commission
Daniel
Greenspan, Esq., Securities and Exchange Commission
Daniel
E. Stoller, Esq., Skadden, Arps, Slate, Meagher & Flom
LLP
Richard
J. Grossman, Esq., Skadden, Arps, Slate, Meagher & Flom
LLP